Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Chanjuan Cui

Chanjuan Cui

Peking University, China

Title: Evaluation of clinical significance of the serum anti-C1q in lupus renal pathological type

Biography

Biography: Chanjuan Cui

Abstract

A prolonged exposure of the first component of the classical pathway of the complement system (C1q) epitopes to the immune system could lead to an autoimmune response against itself. Although the presence of anti-C1q autoantibodies has been described in patients with autoimmune diseases as well as infectious diseases. Interestingly, these autoantibodies are strongly correlated to lupus nephritis (LN). Additionally, it was suggested that anti-C1q autoantibodies could play a role in LN pathogenesis. The aim of our study was to investigate the clinical utility of anti-C1q in predicting renal flares of Systemic lupus erythematosus (SLE) nephritis as well as lupus renal pathology. Serum anti-C1q was tested from 192 SLE patients (including 131 cases with LN and 61cases without LN). The positive rate of anti-C1q in LN was higher than that in non LN with [39.69% (52/131) vs. 21.31% (13/61), P=0.012]. The prevalence of anti-C1q in patients with diffuse proliferative renal lesions (class IV) was higher than that in patients with non-diffuse proliferative renal lesions class (Ⅱ/Ⅲ) (χ2=5.893, P =0.015). In conclution, the serum anti-C1q, a simple, specific and non-invasive biomarker, can objectively reflect LN and effectively guide the clinical judgment of LN pathological types, particularly diffuse proliferative LN (class IV).